Overview

Safety and Efficacy Study for AKB-6548 in Subjects With Chronic Kidney Disease and Anemia

Status:
Completed
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, efficacy, and pharmacokinetics of repeat doses of orally administered AKB-6548 in pre-dialysis subjects with anemia.
Phase:
Phase 2
Details
Lead Sponsor:
Akebia Therapeutics